Independent Conference Coverage from the 2019 Annual Meetings and Conferences. Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc
Latest episodes of the podcast PILOTforPulmonary: 2019 Fall Conference Coverage
- Current Perspective on Antifibrotic Therapy for Patients with IPF
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (The INBUILD Trial)
- Goals of Care Across the Disease Continuum in IPF
- Emerging Diagnostic Approaches to Patients with ILD
- Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease
- Considerations for Geriatric ILD Patients
- Nintedanib for Patients with Systemic Sclerosis-Related Interstitial Lung Disease
- Inhaled NO in Patients at Risk for Pulmonary Hypertension Associated with Pulmonary Fibrosis
- Clinical Pearls from New Orleans 2019
- The IPF Cell Atlas
- Senescence, Senolytics, and IPF
- The PRECISIONS Study
- Genomics and Transcriptomics in PF
- Importance of Pulmonary Fibrosis Patient Registries
- Recent Developments in Methodologies to Support the Diagnosis of IPF
- A New Study Evaluating Pulmonary Rehabilitation Added on to Antifibrotic Therapy
- New Developments in Clinical Trials of Pulmonary Fibrosis
- Exploring Antifibrotic Therapy in Patients with Autoimmune-Associated Interstitial Lung Disease
- Exploring Antifibrotic Therapy in Patients with Autoimmune-Associated Interstitial Lung Disease
- Expanding the Use of Antifibrotic Therapy in Patients with PF
- Considerations for the Management of Autoimmune-Related ILD and Chronic Hypersensitivity-Related ILD
- Key Takeaways from Recent Pulmonary Conferences